No Data
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12
Recursion Pharmaceuticals' Groundbreaking Cancer Drug Enters Clinical Trials
Express News | Recursion Pharmaceuticals Shares up 2.8% Premarket on Getting US FDA Clearance for Early-Stage Cancer Drug Trial
Express News | Recursion Pharmaceuticals Inc - to Initiate Phase 1/2 Dosing of REC-1245 in Q4 2024
Express News | Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-in-Class Rbm39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma